Latest autoimmune diseases Stories
BOTHELL, Wash., Dec. 13, 2012 /PRNewswire-iReach/ -- MediQuest Therapeutics Inc., a specialty pharmaceutical company focused on inflammatory skin diseases and conditions, today announced that they will be conducting partnering/M&A meetings at the J.P. Morgan 31st Annual Healthcare Conference between January 7th and 10th in San Francisco, regarding its Phase 3 topical formulation, VASCANA, designed to treat Raynaud's Disease, an unmet medical need. MediQuest is also selling/licensing the...
OAKLAND, Calif., Dec. 13, 2012 /PRNewswire-USNewswire/ -- The Kenneth Rainin Foundation announced today its 2013 Innovator Awards Program for Inflammatory Bowel Disease (IBD). The Program supports "out-of-the-box" innovative research projects that are potentially transformative to the Foundation's efforts to diagnose, treat and/or cure IBD. The Program is open to tenure track professors (or the equivalent) at all levels from any scientific discipline and from any non-profit research...
INDIANAPOLIS, Dec. 13, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it will stop one of three Phase 3 rheumatoid arthritis (RA) registration studies of tabalumab, an anti-BAFF monoclonal antibody, due to insufficient efficacy. The decision followed a planned interim futility analysis of the FLEX-M study investigating tabalumab, also known as LY2127399, for the treatment of patients with moderate-to-severe RA who had an inadequate response to...
AUSTIN, Texas, Dec. 12, 2012 /PRNewswire/ -- XBiotech Inc., a privately held biotechnology company, today announced positive Phase II clinical trial results in the treatment of acne vulgaris. The trial was conducted as an open label study using XBiotech's lead candidate, True Human(TM) monoclonal antibody MABp1, in patients with moderate to severe disease. Patients enrolled in the study demonstrated continual improvement in lesions over the course of therapy, with up to 42 percent...
ATLANTA, Dec. 11, 2012 /PRNewswire/ -- UCB, Inc. and the Arthritis Foundation are proud to announce the launch of "Everyday Victories," a program designed to celebrate the individual accomplishments of people succeeding with rheumatoid arthritis (RA). The program provides a platform for the 1.5 million Americans impacted by RA to share stories of their personal "everyday victories" over the condition.(1) For each victory submitted by a person living with RA, UCB will provide $1 to...
SAN DIEGO, Dec. 11, 2012 /PRNewswire/ -- Genalyte, Inc. today announced that it has been awarded a Small Business Innovation Research (SBIR) grant to develop multiplexed diagnostic assays for the early detection and monitoring of Type 1 diabetes that will run on Genalyte's innovative Maverick(TM)Detection System. The $500,000 grant is from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health. Genalyte's novel...
BOSTON, Dec. 6, 2012 /PRNewswire/ -- The T1D Exchange, a not-for-profit organization accelerating the discovery of new approaches to type 1 diabetes research and treatment, announced today that Dana Ball has joined the organization as Chief Executive Officer. In his new role, Mr. Ball will oversee the integration and expansion of the T1D Exchange's multiple components, including the clinical registry, biobank and Glu, an online social network for people with type 1 diabetes. Mr....
SAN FRANCISCO, Dec. 6, 2012 /PRNewswire-USNewswire/ -- The nonprofit Scleroderma Research Foundation (SRF) welcomes Andrew Tager, MD to present "New Directions for Scleroderma Treatments: Understanding the Basis for Current Clinical Trials" on December 14, 2012 at 11 a.m. PST. This free webinar will describe current scleroderma clinical trials and new treatments on the horizon. Dr. Tager is Assistant Professor of Medicine at Harvard Medical School, with appointments in the Center...
MOUNTAIN VIEW, Calif., Dec. 5, 2012 /PRNewswire/ -- The challenges inherent in the pharmacological management of rheumatic diseases have stoked huge demand for drug classes with excellent safety and efficacy profiles. While tumor necrosis factor (TNF) inhibitors have greatly enhanced the treatment of these incurable chronic conditions, their unpredictable and inconsistent efficacy as well as their high cost, potential side effects, and uncomfortable mode of delivery (by injection)...
ATLANTA, Nov. 30, 2012 /PRNewswire/ -- In recognition of Crohn's and Colitis Awareness Week (December 1-7), UCB, Inc. is directing a national effort to educate the public about Crohn's disease and inspire those living with the condition to speak out about it. The campaign will hinge on real stories from real people succeeding in the face of Crohn's disease, adding clarity to a misunderstood condition while providing a platform for Crohn's patients to engage and draw support from...
